Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute of Allergy and Infectious Diseases (NIAID) |
---|---|
Information provided by: | National Institutes of Health Clinical Center (CC) |
ClinicalTrials.gov Identifier: | NCT00889616 |
This Phase I study will evaluate the blood stage P. falciparummalaria vaccine candidate BSAM-2/Alhydrogel® (Registered Trademark)+CPG 7909 in adults in the US; and Mali. BSAM-2 contains a mixture of two proteins found on the surface of merozoites, AMA1 and MSP1(42). The study is open label, dose escalating in the US, and will be single-blinded and randomized with a licensed comparator vaccine (Recombivax HB® (Registered Trademark) Hepatitis B) in Mali. All volunteers will receive three doses of vaccine, given at 0, 2, and 6 months and administered in the deltoid muscle. The US arm of the study will be conducted at the Center for Immunization Research (CIR), in Washington DC. Fifteen (15) healthy volunteers will receive 40 (micro)g BSAM-2/Alhydrogel® (Registered Trademark)+500 (micro)g CPG 7909 at CIR, followed by another 15 who will receive 160 (micro)g BSAM-2/Altlhydrogel® (Registered Trademark)+500 (micro)g CPG 7909. Safety data to at least one week after the second vaccination from all US volunteers will be reviewed by a Safety Monitoring Committee prior to vaccinating volunteers in Mali. The highest safe dose will be administered in Mali after safety data in US adults have been reviewed by the SMC. The Mali arm of the study will be conducted in Bancoumana. Thirty (30) volunteers will be randomized to receive either BSAM 2/Alhydrogel® (Registered Trademark)+CPG7909 or the licensed comparator vaccine. The primary objective of the study is to demonstrate safety and reactogenicity of the vaccine in both malaria naive and semi-immune adults. Secondary objectives are to determine the antibody response of the combination vaccine to the AMA1 and MSPl(42) proteins, as measured by antibody levels and parasite growth inhibition. Study endpoints are the incidence of local and systemic adverse events, antibody responses to AMA1 and MSP1(42) proteins, and in vitro growth inhibition of falciparum parasites.
Exploratory immunologic analyses will also be conducted.
Condition | Intervention | Phase |
---|---|---|
Malaria |
Biological: BSAM-2/Alhydrogel + CPG7909 Drug: BSAM2/Alhydrogel + CPG 7909 |
Phase I |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety Study |
Official Title: | Phase 1 Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel® (Registered Trademark)+CPG 7909, an Asexual Blood Stage Vaccine for Plasmodiumfalciparum Malaria in Adults in the US and Mali |
Estimated Enrollment: | 400 |
Study Start Date: | April 2009 |
This Phase I study will evaluate the blood stage P. falciparummalaria vaccine candidate BSAM-2/Alhydrogel® (Registered Trademark)+CPG 7909 in adults in the US; and Mali. BSAM-2 contains a mixture of two proteins found on the surface of merozoites, AMA1 and MSP1(42). The study is open label, dose escalating in the US, and will be single-blinded and randomized with a licensed comparator vaccine (Recombivax HB® (Registered Trademark) Hepatitis B) in Mali. All volunteers will receive three doses of vaccine, given at 0, 2, and 6 months and administered in the deltoid muscle. The US arm of the study will be conducted at the Center for Immunization Research (CIR), in Washington DC. Fifteen (15) healthy volunteers will receive 40 (micro)g BSAM-2/Alhydrogel® (Registered Trademark)+500 (micro)g CPG 7909 at CIR, followed by another 15 who will receive 160 (micro)g BSAM-2/Altlhydrogel® (Registered Trademark)+500 (micro)g CPG 7909. Safety data to at least one week after the second vaccination from all US volunteers will be reviewed by a Safety Monitoring Committee prior to vaccinating volunteers in Mali. The highest safe dose will be administered in Mali after safety data in US adults have been reviewed by the SMC. The Mali arm of the study will be conducted in Bancoumana. Thirty (30) volunteers will be randomized to receive either BSAM 2/Alhydrogel® (Registered Trademark)+CPG7909 or the licensed comparator vaccine. The primary objective of the study is to demonstrate safety and reactogenicity of the vaccine in both malaria naive and semi-immune adults. Secondary objectives are to determine the antibody response of the combination vaccine to the AMA1 and MSPl(42) proteins, as measured by antibody levels and parasite growth inhibition. Study endpoints are the incidence of local and systemic adverse events, antibody responses to AMA1 and MSP1(42) proteins, and in vitro growth inhibition of falciparum parasites.
Exploratory immunologic analyses will also be conducted.
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
All of the following criteria must be fulfilled for a volunteer to participate in this trial:
EXCLUSION CRITERIA (US):
A volunteer will be excluded from participating in this trial if any one of the following criteria is fulfilled:
Severe asthma. This will be defined as:
EXCLUSION CRITERIA (MALI):
A volunteer will be excluded from participating in this trial if any one of the following criteria is fulfilled:
Severe asthma. This will be defined as:
Contact: Ruth D. Ellis, M.D. | (703) 350-1936 | ellisru@niaid.nih.gov |
United States, Maryland | |
Johns Hopkins University | Recruiting |
Baltimore, Maryland, United States, 21205 | |
Mali | |
Malaria Research and Training Center | Recruiting |
Bamako, Mali |
Study ID Numbers: | 999909134, 09-I-N134 |
Study First Received: | April 28, 2009 |
Last Updated: | May 7, 2009 |
ClinicalTrials.gov Identifier: | NCT00889616 History of Changes |
Health Authority: | United States: Federal Government |
Malaria Asexual Blood Stafe Plasmodium Falciparum Immunogenicity Safety |
Protozoan Infections Immunologic Factors Adjuvants, Immunologic Antacids |
Parasitic Diseases Malaria Aluminum Hydroxide |
Protozoan Infections Immunologic Factors Molecular Mechanisms of Pharmacological Action Coccidiosis Physiological Effects of Drugs Adjuvants, Immunologic |
Antacids Parasitic Diseases Malaria Pharmacologic Actions Aluminum Hydroxide |